JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SOMANI, P.
Right arrow Articles by WATSON, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SOMANI, P.
Right arrow Articles by WATSON, D. L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 164, Issue 2, 317-325, 1968
Copyright © 1968 by American Society for Pharmacology and Experimental Therapeutics

ANTIARRUYTHMIC ACTIVITY OF THE DEXTRO- AND LEVO-ROTATORY ISOMERS OF 4-(2-ISOPROPYLAMINO-1-HYDROXYETHYL) METHANESULFONANILIDE (MJ 1999)

P. SOMANI 1 and D. L. WATSON 1

1 Department of Pharmacology, Marquette School of Medicine, Milwaukee, Wisconsin

The antiarrhythmic activity of levo- and dextro-rotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide (MJ 1999), a beta adrenergic receptor blocking agent, was investigated in the present work. levo-MJ 1999, which is the active isomer in terms of blockade of the beta receptors, antagonized adrenergically induced ventricular tachycardia and ventricular fibrillation in 0.5 to 1 mg/kg dose but was ineffective against the arrhythmias produced by toxic dose of ouabain or by two-stage coronary artery ligation in cumulative doses of 25 to 35 mg/kg. In the case of dextro-MJ 1999, 10 to 20 mg/kg dose was needed to suppress adrenergically induced arrhythmias. It is concluded that the antiarrhythmic effects of MJ 1999 are a reflection of the specific beta receptor blocking action of the drug and that MJ 1999 is devoid of the nonspecific antiarrhythmic actions seen with some other beta adrenergic blocking agents.

Submitted on June 4, 1968
Accepted on September 16, 1968




This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
D. A. Lathrop, A. Varro, P. P. Nanasi, I. Bodi, E. Takyi, and C. Pankucsi
Differences in the Effects of d- and dl-Sotalol on Isolated Human Ventricular Muscle: Electromechanical Activity After Beta-Adrenoceptor Stimulation
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 65 - 73.
[Abstract] [PDF]

Home page
 CirculationHome page
S. H. Hohnloser, T. Meinertz, P. Stubbs, H. J.G.M. Crijns, J.-J. Blanc, P. Rizzon, and B. Cheuvart
Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy : Results of a Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study
Circulation, September 15, 1995; 92(6): 1517 - 1525.
[Abstract] [Full Text]

Home page
 NEJMHome page
S. H. Hohnloser and R. L. Woosley
Sotalol
N. Engl. J. Med., July 7, 1994; 331(1): 31 - 38.
[Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1968 by the American Society for Pharmacology and Experimental Therapeutics.